Home > Insider Trading > Filing (0001104659-16-126659)

Filing Details

Accession Number:: 0001104659-16-126659
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-10 21:16:18
Reporting Period:: 2016-06-08

Filing Date:: 2016-06-10
Accepted Time:: 2016-06-10 21:16:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1419600	Flexion Therapeutics Inc	FLXN	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1181338	Md A Ross Jaffe	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1201580	D Samuel Colella	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1201585	B Rebecca Robertson	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1228684	Phd J William Link	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1266567	G Brian Atwood	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1279660	B Donald Milder	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456585	Versant Side Fund Iii, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456586	Versant Venture Capital Iii, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1456587	Versant Ventures Iii, Llc	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No
1597416	Versant Development Fund Iii, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-06-08	710,091	$14.00	3,511,670	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2016-06-08	4,194	$14.00	20,739	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	388,683	Indirect	See Footnote

Footnotes

The shares are held by Versant Venture Capital III, L.P. ("VVC III"). Versant Ventures III, LLC, a Delaware limited liability company ("VV III") serves as the sole general partner of VVC III. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and dispositive power over the shares held by VVC III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
The shares are held by Versant Side Fund III, L.P. ("VSF III"). VV III serves as the sole general partner of VSF III. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and dispositive power over the shares held by VSF III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.
The shares are held by Versant Development Fund III, LLC ("Development III"). Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L Praeger and Barbara N. Lubash are managing directors and/or members of VV III and share voting and investment authority over the shares held by Development III; however, they disclaim beneficial ownership of the shares held by such entities except to the extent of their pecuniary interests therein. Samuel D. Colella is a director of the Issuer and, accordingly, files separate Section 16 reports.